Treatment of basal cell carcinoma with HeberFERON®: clinical study

Objective: To evaluate the effectiveness of HeberFERON® in the treatment of basal cell carcinoma (BCC) in patients treated at the “Dr. Juan Bruno Zayas Alfonso” General Teaching Hospital. Methods: An observational, descriptive and longitudinal study was conducted in patients with facial BCC treated with HeberFERON®. Sociodemographic variables, tumor characteristics, response to treatment and adverse effects were analyzed. Results: 20 patients were included, predominantly male (55%) and the age group 60 years or older (65%). The nodular type was the most frequent (40%) and the most common location was the nasal region (48.1%). 70% of patients had a complete response to treatment. The most frequent adverse reactions were arthralgia (28.1%), general malaise (25.2%) and fever (20.0%). Conclusion: HeberFERON® is an effective therapeutic alternative for BCC, reducing the need for surgery and preserving facial aesthetics.